• de
  • en
deen

International

Berlin Chemie
  • About us
    • BERLIN-CHEMIE
    • MENARINI Group
    • Our History
    • Our Goal
    • Executive Board
    • Contact
  • Responsibility
    • Code of Conduct
    • Sustainability & social commitment
    • Code of practice for business partners
  • Press
    • News and Press Releases
    • Media library
  • Jobs & Careers
  • About us
    • BERLIN-CHEMIE
      • Manufacturing & Quality assurance
      • Business Development
    • MENARINI Group
    • Our History
    • Our Goal
    • Executive Board
    • Contact
  • Responsibility
    • Code of Conduct
    • Sustainability & social commitment
    • Code of practice for business partners
  • Press
    • News and Press Releases
    • Media library
  • Jobs & Careers
  • Home >>
  • Contact >>
  • Purchasing Terms >>
  • Quality Requirements API / EXC >>
  • Data Protection Information Notice for Healthcare Professionals >>
  • Data Protection Information Notice for Patients >>
  • Privacy >>
  • Disclaimer >>
  • Imprint >>
  • Sitemap >>
  • Change cookie settings »

News and Press Releases

Press|News and Press Releases
  • News and Press Releases
  • Media library

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in

Monday, January 30, 2023
Read more

LAST NEWS

Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant

7/23/2020
Read more

Menarini Group Completes Acquisition of Stemline Therapeutics

6/10/2020
Read more

Menarini invests 150 million euros in a new pharmaceutical plant in Italy

6/6/2020
Read more

Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

5/4/2020
Read more

Helsinn Group Grants Exclusive Licensing Rights to BERLIN-CHEMIE for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region

1/27/2020
Read more

MENARINI: Elcin Barker Ergun appointed as Group CEO

9/12/2019
Read more
Previous1234NextLast

News archive

Archive

  • Expand/Collapse 2023 (2)
    • 2023, January (2)
  • Expand/Collapse 2022 (5)
    • 2022, October (1)
    • 2022, September (1)
    • 2022, July (1)
    • 2022, May (2)
  • Expand/Collapse 2021 (3)
    • 2021, November (1)
    • 2021, October (1)
    • 2021, April (1)
  • Expand/Collapse 2020 (7)
    • 2020, November (1)
    • 2020, October (1)
    • 2020, July (1)
    • 2020, June (2)
    • 2020, May (1)
    • 2020, January (1)
  • Expand/Collapse 2019 (1)
    • 2019, September (1)
  • Expand/Collapse 2018 (5)
    • 2018, December (1)
    • 2018, October (1)
    • 2018, September (1)
    • 2018, March (2)
  • Expand/Collapse 2017 (4)
    • 2017, June (1)
    • 2017, March (2)
    • 2017, January (1)
  • Expand/Collapse 2016 (6)
    • 2016, December (2)
    • 2016, November (1)
    • 2016, October (1)
    • 2016, May (1)
    • 2016, March (1)

 

Responsibility >>

BERLIN-CHEMIE

International >>

SCROLL TO TOP Berlin Chemie
Berlin Chemie
  • Home
  • Contact
  • Privacy
  • Change cookie settings »
  • Purchasing Terms
  • Quality Requirements API / EXC
  • Imprint
  • Fair Play Menarini
  • Data Protection Information Notice for Healthcare Professionals
  • Data Protection Information Notice for Patients
  • Disclaimer
  • Sitemap

CONTACT
BERLIN-CHEMIE AG - Glienicker Weg 125 - 12489 Berlin - Germany
Tel.: +49 30 6707-0
Directons: » Contact us

© 2023 BERLIN-CHEMIE AG